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OBJECTIVES  
Bleeding disorders can be challenging to evaluate. Recent research has highlighted the 
clinical variability in bleeding symptom expression among defined bleeding problems. 
Moreover, risks for many bleeding disorders are unknown. 
Von Willebrand disease (vWD) is the most common inherited bleeding disorder, but variable 
severity and several classification types mean that diagnosis is often not straightforward. 
 
The authors intend to present the case of a patient with important hemorrhagic diathesis, 
whose diagnostic clarification has been very challenging. 
METHODS  
Female, 30 years old, easy bruises, mainly after pregnancy two years before, 
diagnosis of vWD studied abroad.  Hemogram, coagulation screening tests, 
determination of von Willebrand factor (vWF) and factor VIII levels (HemosIL® 
Reagents), multimers analysis, molecular study (PCR/Direct Sequencing and 
Capillary Electrophoresis in 3130 Genetic Analyzer), platelet aggregation (PFA-
100 and aggregometry, Multiplate ® Analyzer) and thrombin generation (TG) 
studies (CAT – Calibrated Automated Thrombogram, by Stago) were done. 
Study of parents and sister. 
 
 
 
 
 
 
 
 
 
 
 
Bleeding score (BS) 11/-3 to +45 (easy and severe bruising, wounds, dental 
extractions and menorrhagia), blood group 0, one eutocic delivery, no previous 
surgery. Medicated with paroxetine, for depression. 
VWF levels (antigenic and functional) border-line, not less than 30% (3 
samples), normal multimeric distribution (2 samples), molecular analysis showed 
two heterozygotic missense mutations in exon 28 (c.4508 T>C, p.Leu1503Pro 
and c.4517 C>T, p.Ser1506Leu), referenced in association with vWD type 2A 
and a splicing mutation in exon 38, not described. Reduced  TG. 
No deficits of clinically important factors, no dysfibrinogenemia, normal platelets 
number and aggregation studies without changes.  
Mother’s BS 11/-3 to 45, father and sister’s BS not relevant. Parents (2 samples) 
and sister  (1 sample) normal measurements, molecular study is ongoing. 
                                 RESULTS  
-Hayward C.. Diagnosis and management of mild bleeding disorders. Hematology 2005: 423-28 
- Bolton-Maggs et al.. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. 
Haemophilia 2012, 12 (4): 66-72 
- Sadler JE et al.. Update on the pathophysiology and classification of von Willebrand disease: a 
report of the Subcommittee on von Willebrand Factor. JTH, 4: 2103-2124 
- Michiels JJ et al.. Dominant von Willebrand Disease type 2A groups I and II due to missense 
mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Acta 
Haematol 2009; 121:154-166 
- Federici A et al. Clinical and laboratory versus molecular markers for a correct classification of von 
Willebrand disease. Haematologica 2009; 94(5): 610-615 
REFERENCES  
This patient has a bleeding disorder, presenting severe complaints and a positive family  history. 
Platelet disorders and common coagulation factors deficiencies were excluded. 
We consider that the patient does not meet the criteria for the diagnosis of vWD, in light of the current 
classification. 
The reduced  endogenous thrombin potential and peak of TG results found in  CAT, reflect a low  thrombin 
concentration , probably due  to an abnormal secondary haemostasis (it was performed in PPP).  
Other rare bleeding disorders need to be screened. 
CONCLUSIONS  
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Date 
VWF:RCo (%) 
(RV: 50-180) 
(0 BG: 48-202) 
VWF:Ag (%) 
(RV: 50-180) 
(0 BG: 42-141) 
FVIII activity (%) 
(RV: 50-150) 
01/2013 59 (BG) 52 (BG) 68 
03/2013 61 (BG) 61 (BG) 56 
05/2013 51 (BG) 50 (BG) 52 
02/2014 
(Coimbra) 
47,3 43,5 - 
04/2015 
(HSM) 
37 
(60-200) 
Functional - 39 
(50-150) 
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(60-150) 
62 
Control line 
 Patient line 
Normal plasma 
0 
50 
100 
150 
200 
250 
300 
350 
400 
1
 
9
 
1
7
 
2
5
 
3
3
 
4
1
 
4
9
 
5
7
 
6
5
 
7
3
 
8
1
 
8
9
 
9
7
 
1
0
5
 
1
1
3
 
1
2
1
 
1
2
9
 
1
3
7
 
1
4
5
 
1
5
3
 
1
6
1
 
1
6
9
 
1
7
7
 
HP69633_SCPP 6 
Controlo 
VWF and FVIII levels Multimeric Analysis  Thrombin generation (CAT)  
Patient results 
